Primary Aldosteronism
Conditions
Interventions
Eplerenone group:Eplerenone tablets were initiated at a dose of 50 mg/day and titrated to the target dose based on blood pressure and serum potassium levels.
Spironolactone group:Spironolactone tablets were initiated at a dose of 20 mg/day and titrated to the target dose based on blood pressure and serum potassium levels.
Sponsors
Chengdu Integrated TCM&Western Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 to 70 years old. 2.Hypertension: Meeting the diagnostic criteria for hypertension as defined in the Chinese Guidelines for the Prevention and Treatment of Hypertension. 3.Primary Aldosteronism (PA): Meeting the diagnostic criteria for PA as defined in the Expert Consensus on the Diagnosis and Treatment of Primary Aldosteronism (confirmed via aldosterone-to-renin ratio screening and confirmatory tests). 4.Cardiac Function: Left ventricular ejection fraction (LVEF) = 55% as measured by conventional echocardiography. 5.Biomarkers: NT-proBNP < 125 pg/ml. 6.Consent: Voluntary participation with signed informed consent.
Exclusion criteria
Exclusion criteria: 1. History of taking spironolactone, eplerenone, or other aldosterone receptor antagonists within the past 1 year; 2. History of tumor, epilepsy and cerebrovascular disease; 3. Patients with severe lung diseases such as asthma, chronic obstructive pulmonary disease, interstitial lung disease, and severe pulmonary infection; 4. History of heart failure, severe arrhythmia, severe coronary heart disease, valvular disease, myocardial infarction or revascularization; 5. Patients with renal parenchymal hypertension, renovascular hypertension, aortic stenosis, acute or chronic aortic dissection; 6. Patients with severe liver and kidney dysfunction, coagulation dysfunction, severe systemic infection, and severe anemia; 7. Pregnant or lactating patients; 8. Already involved with other clinical investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global Longitudinal Strain;Global Circumferential Strain;Global Radial Strain;Global Work Index;Global Constructive Work ;Global Wasted Work;Global Work Efficiency;Left Atrial Volume Index;Ratio of peak early to late diastolic mitral inflow velocity;Peak tricuspid regurgitation velocity;Ratio of peak early diastolic mitral inflow velocity to peak mitral annular velocity; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour Ambulatory Blood Pressure;Office Systolic Blood Pressure;Office Diastolic Blood Pressure;Serum Potassium;Plasma Renin Concentration (Supine);Plasma Renin Concentration (Upright);Plasma Aldosterone (Supine);Plasma Aldosterone (Upright);Aldosterone-Renin Ratio (Supine);Aldosterone-Renin Ratio (Upright); Blood Urea Level;Serum Creatinine;Estimated Glomerular Filtration Rate;Left Ventricular End-Diastolic Diameter;Left Ventricular End-Systolic Diameter;Interventricular Septal Thickness;Left Atrial Diameter;Left Ventricular Posterior Wall Thickness; | — |
Countries
China
Contacts
Public ContactHe Wei
Chengdu Integrated TCM&Western Medicine Hospital
Outcome results
None listed